Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Originally developed as an anti-obesity drug candidate in the late 1990s, it has since found research applications in both metabolic studies and cartilage repair investigations
Levels decline with age, which is one reason researchers are studying exogenous administration as a longevity intervention
Safety animal and some human data profiles generally look good, but clinical fertility trials are sparse
Store refrigerated, protected from light
Cagrilintide (Long-Acting Amylin Analog) Amino acid sequence modified from native human amylin [3] Fatty acid acylation extends half-life to approximately 7 days [2] Selective amylin receptor agonist (AMY1, AMY2, AMY3) [4] Delays gastric emptying and reduces food intake [5] Controls postprandial glucose metabolism [6] Synergistic effects with GLP-1 receptor agonists [7] CagriSema: The Synergistic Combination One of the most significant developments in cagrilintide research is its combination with semaglutide (a GLP-1 receptor agonist), known as CagriSema
US$ 26.71
US$ 22.42
US$ 22.06
US$ 22.65
US$ 29.06
US$ 20.65
US$ 26.95
US$ 27.76
US$ 28.27
US$ 21.62
US$ 20.78
US$ 27.23
